World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 6
Page: 1046-1065

FROM PAPER TO PLATFORMS: THE DIGITAL REINVENTION OF REGULATORY AFFAIRS

Harshada Jadhav*, Sandesh Jadhav, Dr. Rahul Radake

Department of Regulatory affairs, Karmayogi Tatyasaheb Bondre Institute of Pharmacy, Khamgaon Rd, Chikhli, Maharashtra, 443201.

Article Received: 29 April 2026 | | ***Article Revised: 19 May 2026*** | | ***Article Accepted: 09 June 2026***

***Corresponding Author: Harshada Jadhav**
Department of Regulatory affairs, Karmayogi Tatyasaheb Bondre Institute of Pharmacy, Khamgaon Rd, Chikhli, Maharashtra, 443201.
DOI: https://doi.org/10.5281/zenodo.20690276

How to cite this Article: Harshada Jadhav, Sandesh Jadhav, Dr. Rahul Radake (2026) FROM PAPER TO PLATFORMS: THE DIGITAL REINVENTION OF REGULATORY AFFAIRS. World Journal of Pharmaceutical Science and Research, 5(6), 1046-1065.

ABSTRACT

Regulatory Affairs (RA) has emerged as a cornerstone of the pharmaceutical and healthcare ecosystem, bridging innovation, compliance, and patient safety. As drug development becomes increasingly complex and globalized, RA ensures that pharmaceuticals, biologics, medical devices, and novel therapies meet rigorous national and international regulatory standards throughout their lifecycle—from discovery and preclinical evaluation to clinical trials, approval, and post-marketing surveillance. Modern RA integrates digital submission platforms, artificial intelligence, real-world evidence, and patient-centric approaches to streamline regulatory processes, enhance transparency, and accelerate access to safe and effective therapies. Harmonized frameworks, including CTD, eCTD, ACTD, and ICH guidelines, facilitate cross-border approvals and reduce redundancy. The discipline now extends to advanced therapies such as gene and cell therapies, biosimilar, and digital health innovations, reflecting its evolving scope and strategic significance. This review synthesizes the critical roles, regulatory frameworks, emerging trends, and future directions of RA, highlighting its indispensable contribution to public health, innovation, and sustainable growth in the global healthcare landscape.

KEYWORDS: Regulatory Affairs, Pharmaceutical Industry, CDSCO, Clinical Trials, CTD, eCTD, ACTD, Drug Approval, Post-Marketing Surveillance, Pharmacovigilance, Global Regulatory Harmonization, Digital Submissions.[1]

INTRODUCTION

Regulatory Affairs (RA) serves as a critical interface between the pharmaceutical industry and regulatory authorities, ensuring that drug development, manufacturing, and marketing activities comply with national and international standards. The field encompasses a wide range of specialized responsibilities focused on evaluating and communicating

the safety, quality, and efficacy of healthcare products, including pharmaceuticals, biologics, medical devices, cosmetics, and functional foods. Over time, global regulatory frameworks have evolved in response to safety concerns, resulting in well-defined, structured systems guided by GMP, GLP, and GCP principles. As drug development is a lengthy and complex process involving discovery, preclinical research, and clinical trials, the role of regulatory professionals has become essential. They monitor regulatory changes, prepare and submit dossiers such as INDs, NDAs, ANDAs, MAAs, and CTD/eCTD formats, and support the entire product lifecycle. Their work ensures that only safe, effective, and high-quality products reach patients. Recent public health challenges, such as the COVID-19 pandemic, have further highlighted the importance of efficient regulatory systems in enabling rapid evaluation and approval of critical medical products. Overall, Regulatory Affairs plays a vital role in safeguarding public health by guiding the scientific and legal processes required for the successful introduction of pharmaceutical products into the global market.[2]

Regulatory affairs in pharmaceutical industry



Figure 1: Regulatory Affairs In Pharmaceutical Indusry.

Roles of the Regulatory Affairs Department in the Pharmaceutical Industry

Figure 2: Roles of the Regulatory Affairs Department in the Pharmaceutical Industry.

Regulatory Affairs plays an essential role in connecting all departments of the pharmaceutical industry and ensuring that every step from raw materials to the finished product—follows regulatory standards. By guiding teams, checking documents, and maintaining compliance, the RA department helps the company deliver safe, effective, and high-quality medicines to patients.[3]

Study of various committees across the globe

Regulatory authorities across the world have different requirements for approving pharmaceutical products. Each region follows its own dossier format, submission language, review timeline, and rules for CPP and marketing authorization. Understanding these global regulatory differences helps pharmaceutical companies prepare proper documentation and achieve faster product approval in international markets.

Table 1: Study of various committees across the globe.[4]

Region / Country Group	Regulatory Authority	Dossier Format	Submission Language	CPP	Market Authorization Validity	Registration Time
India	CDSCO	CTD / eCTD	English	Required	5 Years	6–12 Months
United States (USA)	USFDA	eCTD	English	Not Required for NDA	5 Years	10–12 Months
Europe (EU Region)	EMA	eCTD	English	Not Required	5 Years	12–18 Months
United Kingdom (UK)	MHRA	eCTD	English	Not Required	5 Years	12–18 Months
Japan	PMDA	CTD / eCTD	Japanese	Required	5 Years	12–18 Months
Canada	Health Canada	CTD / eCTD	English / French	Required	5 Years	12–18 Months
Australia	TGA	CTD / eCTD	English	Required	5 Years	12–15 Months
Philippines, Myanmar, Vietnam, Thailand	ACTD (ASEAN)	ACTD	English / Local	Required	5 Years	~12 Months
East African Community (EAC)	EAC Authorities	EAC-CTD	English	Required	5 Years	~180 Working Days
Cuba, Latin America (PAHO Region)	CECMED / PAHO	CTD / PAHO	Spanish / English	Required	5 Years	12–24 Months

CDSCO (Central Drugs Standard Control Organization)

The Central Drugs Standard Control Organization (CDSCO) is the national authority that regulates drugs, cosmetics, diagnostics, and medical devices in India. It is headed by the Drugs Controller General of India (DCGI), who is responsible for ensuring the safety, effectiveness, and quality of pharmaceutical and medical device products. CDSCO also publishes the Indian Pharmacopoeia and works with the World Health Organization to promote Good Manufacturing Practices and support international regulatory standards.



Table 2: Organization of CDSCO

Functions

1. Approval of New Drugs – Evaluates and approves new drugs for India.
2. Approval of Clinical Trials – Grants permission for conducting clinical trials.
3. Import/Export Licensing – Issues licenses for import and export of drugs & cosmetics.
4. Quality Control – Ensures safety, efficacy, and quality of drugs and cosmetics.
5. Amendment of Drug Laws – Updates and enforces Drugs & Cosmetics Act & Rules.
6. Banning of Drugs – Prohibits unsafe or ineffective drugs/cosmetics.
7. Regulation of Medical Devices – Controls approval and standards of medical devices.
8. Coordination with State Authorities – Works with state drug controllers for regulation.[5]

Responsibility of CDSCO



Figure 3: Responsibility of CDSCO.

Clinical Drug Development Process

A clinical trial is a research study in which people are given a treatment or health-related intervention to see how it affects their health. Clinical trials are systematic studies conducted to evaluate the safety, effectiveness, and quality of new drugs, medical devices, or interventions before they are approved for public use. These trials follow strict ethical and regulatory guidelines such as GCP to protect participants and ensure reliable results. They are conducted in well-defined phases using different designs like randomized, blinded, and multi-center studies to reduce bias. Proper planning includes protocol writing, CRF preparation, ethics committee approval, and training of investigators.

Monitoring and audits are performed to check whether the trial follows all rules, maintains accurate data, and ensures participant safety. Clinical trials are costly, time-consuming, and require teamwork between sponsors, CROs, investigators, and regulatory authorities to bring a new drug successfully to the market.

Different type of clinical study

Table 3: Different types of clinical study.[6]

Feature	Phase 1	Phase 2	Phase 3	Phase 4
Main Purpose	To check **safety**, tolerability, and find the safe dose	To check **efficacy** and short-term side effects	To confirm **efficacy, safety, and comparison** with standard treatment	To monitor **long-term safety** after approval
Conducted On	Healthy volunteers (sometimes patients)	Patients with the disease	Large patient population	General population using the drug
Sample Size	20–100	100–300	1000–3000 (or more)	Thousands to millions
Key Focus	Safety, PK/PD, dose-escalation, tolerability	Effectiveness, dose optimization, short-term safety	Large-scale safety, long-term efficacy, risk–benefit analysis	Rare side effects, drug interactions, long-term safety
Study Design	Open-label, dose-escalation	Randomized, controlled	Randomized controlled trials (RCTs), double-blind, multi-center	Observational, post-marketing studies
Duration	Months	Several months to 2 years	2–4 years	Ongoing (after marketing)
Regulatory Objective	Safety evaluation before testing in larger groups	Proof of concept and dose selection	Final evidence for **drug approval**	Post-marketing surveillance (PMS)
Endpoints (Outcomes)	Maximum tolerated dose (MTD), side effects, PK/PD	Optimal dose, initial efficacy, short-term safety	Strong evidence of efficacy, safety profile, comparison with standard treatment	Long-term risks, new indications, rare adverse events
Risk Level	Highest (first time in humans)	Moderate	Lower than Phase 1 & 2	Lowest, but important for detecting rare issues

Clinical trial protocol

A clinical trial protocol is a detailed written plan that explains exactly how a clinical study will be carried out. It acts like a guideline for the research team and ensures that the trial is conducted safely, ethically, and scientifically. The protocol includes the purpose of the study, the study design, number of participants, eligibility criteria, treatment procedures, dosing schedule, safety monitoring, and methods for collecting and analyzing data. It follows important ethical and regulatory guidelines such as ich-gcp to protect the rights and safety of the participants. Before a trial begins, the protocol is reviewed by medical experts, statisticians, safety teams, and regulatory specialists to check for

accuracy, completeness, and clarity. This peer review helps avoid mistakes and prevents delays during the trial. A strong, well-written clinical trial protocol ensures smooth study operations, reliable results, and successful regulatory approval.[7]

Phase 1 and Subtype Studies

1. Single Ascending Dose (SAD) Study

A Single Ascending Dose study is the first step in Phase 1 trials. In this study, a small group of participants receives one single dose of the investigational drug. If the dose is found to be safe with no serious side effects, the next group receives a slightly higher dose. This step-by-step increase helps researchers identify the maximum dose that is still safe for humans. SAD studies help understand the drug's short-term safety, tolerability, and basic pharmacokinetic (PK) profile, such as how fast the drug enters the blood and how the body removes it.[8]

2. Multiple Ascending Dose (MAD) Study

A Multiple Ascending Dose study evaluates the safety of repeated dosing over a few days or weeks. Participants receive the drug more than once—often daily—to see how the body handles continuous exposure. Researchers monitor whether the drug accumulates in the body and whether repeated use causes new or stronger side effects. Different dose levels are tested in different groups, increasing gradually like in SAD. MAD studies provide important information on long-term PK behavior, steady-state concentration, and safety under repeated use.[9]

3. Dose Escalation Study

Dose escalation is an important part of Phase 1 research, where the drug dose is increased gradually to find the **Maximum Tolerated Dose (MTD)**. Researchers carefully observe for **Dose-Limiting Toxicities (DLTs)**—side effects that prevent further dose increase. This helps determine the safest and most effective dose range for later phases. Dose escalation can be done using different methods, such as 3+3 design or accelerated titration. The goal is to balance safety with potential treatment benefits.[10]

4. Food Effect Study

A Food Effect study investigates how eating affects the absorption of the drug. The same participants take the drug under two conditions—after fasting and after a high-fat meal. Blood samples are collected to compare drug levels in both situations. Food can increase, decrease, or delay the absorption of a drug. Understanding the food effect helps to give proper instructions to patients, such as whether to take the medicine with food or on an empty stomach. This ensures consistent and safe use of the drug.[11]

5. Drug–Drug Interaction (DDI) Study

A Drug–Drug Interaction study examines how the investigational drug behaves when taken with other commonly used medicines. Some drugs can change how fast another drug is absorbed, broken down, or removed from the body. DDI studies help identify these changes early to prevent harmful side effects or reduced effectiveness. These studies are important especially when the new drug is likely to be used by patients who take multiple medications, such as those with chronic diseases.[12]

6. Pharmacokinetic (PK) Endpoints

PK endpoints are measurements used to understand how the drug moves through the body. Key PK parameters include **Cmax**, the highest concentration of the drug in the blood; **Tmax**, the time it takes to reach Cmax; and **AUC**, which shows the overall exposure to the drug. Other parameters like **half-life (t½)** indicate how long the drug stays in the body, and **clearance** shows how quickly it is removed. These PK results help determine the right dose, dosing frequency, and overall safety profile of the drug.[13]

Phase 2 studies

1. Proof of Concept

Phase 2 trials are called Proof of Concept studies because they show for the first time that a new drug can actually help patients with the disease. In this phase, researchers check if the drug gives real benefits, like reducing symptoms or improving lab test results. They compare the drug's effects with different doses, a placebo, or an existing treatment to see if it works better. If patients show clear improvement and the drug is still safe, it proves that the drug has the potential to treat the disease. This information is very important because it helps decide whether the drug should move on to the larger Phase 3 trials.

2. Principle study to Establishing Efficacy

In Phase 2 studies, one of the main goals is to find out if the drug really works in patients. Researchers check whether the drug improves the patient's symptoms or health condition. They compare how patients feel before and after taking the drug, and sometimes compare the results with a placebo or a standard medicine. This helps them see if the improvement is truly because of the drug. If the drug shows good benefits and helps patients in a meaningful way, then it is considered effective and can move on to the next phase of testing.[14]

Phase 3 studies

1. Multi-Ethnicity Studies

In Phase 3 trials, patients from different ethnic backgrounds are included, such as people from Asia, Africa, Europe, and America. This is done because people with different genetics and lifestyles may react differently to the same medicine. By testing the drug in many ethnic groups, researchers can make sure it works well and is safe for everyone.

This helps avoid mistakes that can happen if the drug is tested only in one region or one type of population.

2. Global Clinical Trials

Phase 3 trials are often done in many countries at the same time. These are called global clinical trials. Doing the study in different places helps researchers collect more accurate and real-world information. Patients from different countries may have different diets, climates, and health conditions, which helps show how the drug works in many situations.

Global trials also help speed up drug development because more patients can join quickly. All these trials follow strict international rules to make sure they are safe and ethical everywhere.

3. Registration Studies

Phase 3 studies are also called registration studies because the results are used to apply for government approval. The information collected from these trials is sent to regulatory authorities like USFDA, EMA, CDSCO, and others. These

agencies check the data to decide if the drug can be sold to the public. Phase 3 provides the strongest evidence that the drug works, is safe, and has the right dose. Without successful Phase 3 results, a drug cannot be approved for use.[15]

Phase 4 studies

1. Post-Marketing Surveillance (PMS)

Post-Marketing Surveillance (PMS) is the process of monitoring a drug's safety after it has been approved and is being used by the general public. Even though a drug passes earlier clinical trial phases, those studies involve only a limited number of people. But once the drug reaches the market, it may be used by millions of patients of different ages, health conditions, and lifestyles. Because of this wide use, some rare, long-term, or unexpected side effects may appear that were not seen during trials. PMS helps collect and analyze reports of these side effects from doctors, hospitals, pharmacists, and even patients. This information is important to identify any new risks and ensure the drug remains safe. If any serious problem is found, regulatory authorities can update the drug's warnings, change the dose, restrict certain uses, or even stop the drug from being sold. PMS plays a very important role in protecting public health.[16]

2. PSUR (Periodic Safety Update Report)

A Periodic Safety Update Report (PSUR) is a regular safety report that pharmaceutical companies must submit to regulatory authorities after the drug is marketed. The PSUR provides updated information about all new side effects, safety concerns, or adverse reactions reported by patients and healthcare professionals. It includes data from hospitals, scientific studies, and even other countries. The report also contains a benefit–risk analysis that shows whether the drug's benefits still outweigh its risks. PSURs are submitted every few months or yearly, depending on the regulatory rules. Authorities review these reports carefully to decide if the drug's label needs new warnings, if more studies are required, or if any safety action is needed. PSURs ensure that the drug continues to be safe throughout its market life and helps protect patients from any new risks.[17]

Documentation in Pharmaceutical Industry

Exploratory Product Development Brief

Exploratory product development is the early stage of drug development where scientists study a new drug molecule to understand its basic properties and to prepare an initial, simple drug product. The main aim is to collect enough information so that the drug can safely move into further development and clinical trials. This step helps to identify problems early, save cost, and select the most suitable form of the drug.[18]

Exploratory Development of Drug Substance (API)

In this stage, the new chemical entity (NCE) is studied in detail to understand how it behaves physically and chemically. This helps in deciding whether the API is suitable for formulation.

a) Physicochemical Properties

In this step, scientists study the basic physical and chemical properties of the new drug.

- Solubility in water and solvents
- pKa, logP, hygroscopicity
- Particle size and flow properties
- Polymorphism (different crystal forms)

This information helps decide how the drug should be stored and what type of formulation will suit it.

b) Impurity Profiling

Here, the drug is tested to identify any impurity or unwanted chemicals present during synthesis. Scientists also check how the drug breaks down under different conditions like heat, light, or humidity. This helps in making the drug safer and choosing better manufacturing conditions.

- Identifying impurities in the API
- Studying how the drug degrades
- Planning how to control impurities[19]

c) Stability Studies

In this stage, the drug is exposed to stress conditions such as high temperature, strong light, moisture, and oxidation. This helps to understand how stable the drug is and how it degrades. Based on this, storage conditions and packaging needs are decided

- Testing API under heat, light, humidity
- Finding degradation products
- Choosing proper storage conditions

d) Synthetic Route Development

Scientists develop and test different methods to synthesize the drug**.** The aim is to find a route that is safe**,** easy**,** cost-effective, and suitable for scaling up. They also identify the best raw materials to use in manufacturing.

- Finding the best pathway to make the API
- Checking safety, cost, and feasibility[20]

e) Excipient Compatibility

The drug is mixed with different excipients to see if they react with each other. If the drug shows bad interactions, those excipients are avoided in the final formulation. This helps in selecting safe and stable formulation components.

- Checking how API reacts with common excipients
- Helps in selecting suitable formulation ingredients[21]

2. Exploratory Development of the Drug Product (Formulation)

This stage focuses on converting the API into an early **prototype dosage form** (tablet, capsule, injection, etc.). The aim is not to make the final product but to check what type of formulation will work best.

a) Preformulation Studies

In this stage, scientists study how the drug behaves with different excipients and in different pH or solvent systems. This helps in deciding whether the drug needs solubility enhancement or stabilizers. The aim is to understand how the drug will perform in a formulation.

- Drug–excipient compatibility
- Solubility and dissolution profile
- Solid-state behavior

b) Prototype Formulations

Simple, small-scale trial formulations (tablets, capsules, injections, suspensions) are prepared. Different excipients are tested to find the best combination. The purpose is to make an initial product that is safe and acceptable for early testing**.**

- Preparing small batches of tablets, capsules, or solutions
- Testing different excipients
- Checking if the formulation gives enough stability and bioavailability

c) Bioavailability Improvement

The prototype products are tested to see how fast and how much drug gets released. If the drug shows poor absorption, techniques like nanoparticles, lipids, or solid dispersions are tried. This helps predict how well the drug will work in the body. If the drug is poorly soluble, techniques such as solid dispersion, nanoparticles, or lipid-based systems are tried.

d) Preliminary Manufacturing Studies

Scientists test small-scale manufacturing methods such as mixing**,** granulation**,** compression**,** or filling to see how easily the product can be made. They identify important steps (CPPs) that affect product quality. This helps prepare for large-scale production later.

- Checking blend uniformity, compressibility, granulation
- Identifying basic critical process parameters

e) Stability Testing

The trial product is kept under accelerated conditions (high temperature and humidity) to check its stability. Changes in color, hardness, dissolution, or potency are noted. Based on this, packaging materials like blisters or bottles are selected.

- Short-term accelerated stability of prototype dosage form
- Helps in selecting suitable packaging and storage conditions

f) Route of Administration and Strength Selection

Based on preclinical and early human data, the most suitable route (oral, injection, topical, inhalation) is selected. The first dose strength is decided for Phase 1 clinical trials. This helps design safe and effective early formulations.

- Deciding whether the drug will be oral, injectable, topical, etc.
- Selecting a suitable dose for early clinical trials[22]

Common Technical Document (CTD)

The Common Technical Document (CTD) is a **standard format** used by pharmaceutical companies to submit information to drug regulatory authorities for approval of medicines. It was developed by the **International Council for Harmonisation (ICH)** to reduce differences in drug approval requirements among various countries. Earlier, companies had to prepare separate dossiers for each country, which required more time, money, and effort. CTD was introduced to make the submission process **uniform, systematic, and easy to understand.** It is used for different types of products such as **new drugs, generic drugs, biologics, and biosimilar.** Today, most regulatory authorities accept submissions in **electronic form called eCTD,** which helps in faster review and better document management.[23]

Structure of CTD

The CTD is divided into **five main modules**, and each module contains a specific type of information. These modules are arranged in a logical order so that regulatory authorities can easily review the data. Module 1 contains administrative information, Module 2 provides summaries of scientific data, Module 3 deals with product quality, Module 4 includes non-clinical study data, and Module 5 contains clinical study reports. Together, these modules provide complete information about the quality, safety, and effectiveness of a drug.

Table 4: Modules of CTD[24]

Module	Title / Name	Contents	Purpose / Importance
Module 1	Administrative & Regional Information	Application forms, cover letters, labeling (package insert, patient leaflet), patent info, Certificate of Pharmaceutical Product (CPP), risk management plan, correspondence with regulatory authorities	Ensures compliance with country-specific laws and administrative requirements
Module 2	CTD Summaries & Overviews	Quality Overall Summary (QOS), non-clinical summary, clinical summary, benefit–risk overview	Provides a quick summary of Modules 3, 4, and 5 for easy regulatory review
Module 3	Quality (Chemical, Manufacturing, Controls – CMC)	Drug substance (API) & drug product info, manufacturing process, raw materials, in-process controls, specifications, analytical methods, validation, batch analysis, stability studies	Ensures drug is consistently manufactured, high-quality, and GMP compliant
Module 4	Non-Clinical Study Reports	Pharmacology, pharmacokinetics (ADME), toxicology studies (acute, repeated-dose, genotoxicity, carcinogenicity, reproductive)	Evaluates safety of the drug before human trials; helps decide safe starting dose
Module 5	Clinical Study Reports	Phase I, II, III clinical trial reports, bioavailability & bioequivalence studies (for generics), post-marketing data	Confirms drug is safe, effective, and beneficial for patients; used for final approval

Electronic Common Technical Document (eCTD)

The Electronic Common Technical Document (eCTD) is the digital version of the Common Technical Document (CTD) used for submitting regulatory dossiers to health authorities. It was developed by the ICH to replace paper-based submissions and make the regulatory process faster, more organized, and efficient. Regulatory agencies such as the USFDA, EMA, PMDA (Japan), and Health Canada now prefer or require eCTD submissions. Using eCTD allows pharmaceutical companies to submit documents electronically, track submission status, and maintain proper records of all updates and amendment. Before eCTD, submissions were made on paper, which created several challenges. Paper dossiers were bulky, difficult to manage, and hard to store. Reviewing such large documents was time-consuming, and updating or correcting them was prone to errors. Tracking amendments, variations, or supplements was complicated.

eCTD solves these issues by providing a standardized electronic format that allows quick navigation, easy document retrieval, and efficient lifecycle management. It also reduces duplication and improves communication between regulatory authorities and pharmaceutical companies.[25]

Table 5: Modules of eCTD[26]

Module	Name	Contents	Purpose
Module 1	Administrative & Regional Info	Forms, letters, labeling, patents, CPP, correspondence	Follows country rules and legal requirements
Module 2	Summaries & Overviews	Quality summary, non-clinical & clinical summary, benefit–risk	Gives quick overview of all data
Module 3	Quality (CMC)	API & product info, manufacturing, controls, stability	Ensures drug is high-quality & GMP compliant

Module 4	Non-Clinical Reports	Animal studies: pharmacology, ADME, toxicology	Checks safety before humans
Module 5	Clinical Reports	Human studies: Phase I-III, bioavailability, post-marketing	Confirms drug is safe & effective
eCTD Features	Electronic Components	XML backbone, PDFs, bookmarks, hyperlinks, lifecycle tracking	Makes submission organized & easy to track

ASEAN Common Technical Dossier (ACTD)

The ASEAN Common Technical Dossier (ACTD**)** is a standardized format used for submitting applications for drug approval in ASEAN countries. Its primary goal is to harmonize the submission process, reduce duplication of work, and make regulatory approvals faster and easier for both authorities and pharmaceutical companies. Before submitting an ACTD, it is crucial to organize and validate the dossier properly. Organization ensures that all documents are arranged in the correct order, easy to read, and easy for regulators to navigate. Validation ensures that the dossier is complete, accurate, and compliant with the specific guidelines of the country. Together**,** proper organization and validation improve the chances of approval and reduce delays caused by queries or missing information.[27]

Table 6: Features of ACTD[28]

Module	Name	Contents	Purpose / Importance
Module 1	Administrative Info	Forms, letters, patient leaflets, GMP certificates, correspondence with authority	Follows country rules and legal requirements
Module 2	Summaries & Overviews	Quality summary, animal study summary, human study summary, benefit–risk overview	Gives quick overview of all data for easy review
Module 3	Quality (CMC)	Drug substance (API) & product info, manufacturing steps, testing, stability, packaging	Ensures drug is high-quality, safe, and GMP compliant
Module 4	Non-Clinical Studies	Animal studies: how drug works, ADME (absorption, distribution, metabolism, excretion), toxicity	Checks safety before testing in humans
Module 5	Clinical Studies	Human trials: Phase I-III, bioavailability/bioequivalence, post-marketing data	Confirms drug is safe and effective for patients
Organization	Arranging Documents	Collect all files, put in correct module, number pages, add headings and table of contents	Makes dossier easy to read and review
Validation	Checking Accuracy & Completeness	Check all modules included, format correct, data consistent, files open properly, final review	Ensures dossier is complete, accurate, and ready for submission
Tools	Helping Tools	Checklists, PDF software, document management systems, cross-reference tables	Helps organize and validate documents efficiently

CDSCO Sugam Portal

The Sugam portal is the official online submission and tracking system of CDSCO (Central Drugs Standard Control Organization) in India. It was developed to replace traditional paper-based submissions with a digital platform. The main goal of Sugam is to make drug approvals faster, easier, transparent, and more efficient**.** Through this portal,

pharmaceutical companies, sponsors, and manufacturers can submit applications for new drugs, clinical trials, manufacturing or import licenses, generic drug registrations, biologics, biosimilars, and post-approval changes such as renewals or variations. The portal also allows both the applicant and CDSCO officials to track the status of applications in real time**,** reducing delays and improving communication.

Need for the SUGAM Portal

Before the introduction of the SUGAM portal, regulatory submissions in India were completely paper-based. This system was time-consuming and involved delays due to printing, couriering, and manual handling of documents. Applicants had no clear way to track the progress of their applications, which resulted in lack of transparency. There was also a high risk of document loss, missing information, and increased costs related to physical storage and transportation. The SUGAM portal was introduced to overcome these challenges by providing a centralized, electronic submission and tracking system.[29]

Features of the SUGAM Portal

The SUGAM portal provides several important features that simplify the regulatory submission process. It allows online submission of application forms and supporting documents, ensuring a paperless process. Applicants can track their application status in real time. The portal offers secure data upload, protecting confidential regulatory information. Online fee payment facilities are also available. Additionally, the system enables direct communication between applicants and CDSCO through online queries, responses, and notifications.

Types of Applications Submitted through SUGAM

The SUGAM portal supports submission of various regulatory applications. These include New Drug Applications for approval of new chemical entities, formulations, biologics, and biosimilars. Clinical Trial Applications can be submitted to obtain permission to conduct clinical studies in India. The portal also supports applications for import licenses, manufacturing licenses, post-approval variations such as changes in manufacturing site or labeling, and renewal of existing approvals. Each application submitted through SUGAM is assigned a unique application number for tracking.[30]

Registration Process

To submit applications through the SUGAM portal, the applicant must first complete online registration. During registration, details of the organization, authorized signatory, email address, and contact number are provided. Required supporting documents are uploaded for verification by CDSCO. Once the registration is reviewed and approved, login credentials are activated, allowing the applicant to access the portal and submit applications.

Step-by-Step Submission Process

After successful login, the applicant selects the appropriate application type based on regulatory requirements. The online application form is then filled with accurate and complete information. Supporting documents such as administrative documents, quality data, clinical and non-clinical study reports, and certificates are uploaded in the prescribed format. Application fees are paid online through the portal. Before final submission, the application is reviewed to ensure completeness and correctness. Once submitted, the system generates an acknowledgment along with a unique application number.[31]

Advantages of Submission through SUGAM

The SUGAM portal offers several advantages over the traditional paper-based system. It significantly reduces submission and approval timelines. Real-time tracking improves transparency and accountability. Built-in system checks reduce errors and missing documents. The portal ensures secure handling of regulatory data and reduces costs related to printing and courier services. Overall, it makes the regulatory process faster, more reliable, and user-friendly.[31]

Challenges in Regulatory Affairs

- Regulatory Affairs professionals face many difficulties because rules and regulations keep changing. One major challenge is **frequent updates in regulatory guidelines.** Regulatory authorities often change laws to improve drug safety, so regulatory professionals must always stay updated and follow the latest rules.
- Another challenge is that **different countries have different regulatory requirements**. Each country has its own approval process, documents, and timelines. Preparing separate submissions for different countries is difficult and time-consuming.
- **Documentation work is very heavy in regulatory affairs**. Large numbers of documents such as applications, study reports, and safety data must be prepared carefully. Even a small mistake can delay approval.
- **Approval delays** are also a common challenge. Regulatory authorities may ask questions or request additional data, which increases the approval time and cost.
- After a drug is approved, **managing post-approval changes** becomes challenging. Any change in manufacturing, labeling, or packaging must be reported to authorities. Regular safety reports like PSURs must also be submitted on time.
- **Regulatory inspections and audits** are another challenge. Companies must always follow GMP, GCP, and GLP guidelines. Any non-compliance can lead to warnings or product rejection.
- New technologies such as **biologics and advanced therapies** create additional challenges because regulatory guidelines for these products are still developing.
- Finally, **lack of trained regulatory professionals** and high workload make regulatory work more difficult and stressful.[32]

Recent Trends and Updates in Regulatory Affairs (2025–2026)

In recent years, regulatory affairs has experienced major changes due to rapid technological development, globalization of the pharmaceutical industry, and increasing focus on patient safety. Regulatory authorities are continuously updating their systems and guidelines to ensure that safe, effective, and high-quality medicines reach patients faster while maintaining strict control.

1. Digital Transformation of Regulatory Submissions

One of the most important recent trends in regulatory affairs is the shift from paper-based submissions to fully digital submissions**.** Regulatory agencies such as the USFDA, EMA, and CDSCO now prefer or mandate electronic submissions in formats like **eCTD.** Cloud-based submission platforms allow companies to submit applications online, manage documents efficiently, and respond to regulatory queries faster. Digital submissions improve review speed, reduce errors, and save time and cost. However, regulatory authorities and companies must ensure data security, system compatibility, and proper document control.

2. Use of Artificial Intelligence (AI) and Automation

Artificial Intelligence and automation are increasingly being used in regulatory affairs to handle complex and large volumes of data. AI tools help **in** adverse event detection, document review, regulatory writing, and tracking submission timelines**.** Automation reduces manual workload, minimizes human errors, and improves consistency in regulatory documentation. Despite these benefits, human expertise is still essential to validate AI-generated outputs and ensure regulatory compliance.

3. Increased Use of Real-World Evidence (RWE)

Regulatory authorities are now placing more importance on real-world evidence (RWE) in decision-making. RWE is collected from real-life sources such as hospital records, patient registries, insurance data, mobile health apps, and wearable devices. This data helps regulators understand how a medicine performs in real-world conditions, beyond controlled clinical trials. RWE supports safety monitoring, effectiveness evaluation, and post-approval decisions, making regulatory assessments more patient-focused.

4. Patient-Centric Regulatory Approach

A significant recent update in regulatory affairs is the shift toward **patient-centric decision-making.** Regulatory authorities now consider patient experiences, preferences, and reported outcomes during drug evaluation. Patient-reported outcomes (PROs) are used to understand treatment benefits, side effects, and quality of life. This approach ensures that regulatory decisions focus not only on scientific data but also on patient needs and expectations.[33]

5. Global Regulatory Harmonization

Global regulatory harmonization is another major trend shaping regulatory affairs. International organizations such as **ICH and PIC/S** are working to align guidelines related to quality, safety, and efficacy across countries. Harmonized standards help pharmaceutical companies prepare common regulatory dossiers for multiple regions, reduce duplication of studies, and speed up global approvals. Although complete harmonization has not yet been achieved, continuous collaboration among regulatory agencies is improving consistency worldwide.

6. Accelerated and Adaptive Approval Pathways

Regulatory authorities are expanding **fast-track and accelerated approval pathways** for critical and innovative therapies. These pathways are especially important for medicines treating cancer, rare diseases, and life-threatening conditions. Programs like accelerated approval allow early access to medicines based on promising data, with continued monitoring after approval. This trend balances the need for rapid patient access with strict safety evaluation.

7. Strengthening of Post-Marketing Surveillance and Pharmacovigilance

Post-marketing safety monitoring has become more robust in recent years. Regulatory agencies now require **more detailed and frequent safety reporting**, including PSURs and risk management plans. Patient-reported safety data and real-world safety signals are closely monitored. This ensures that any rare or long-term side effects are identified early, and regulatory actions such as label updates or restrictions can be taken to protect public health.

8. Regulation of Advanced Therapies and New Technologies

With the growth of **biologics, biosimilar, gene therapy, cell therapy, and digital health products**, regulatory frameworks are continuously evolving. New guidelines are being developed for digital therapeutics, AI-based medical

devices, and telemedicine tools. Regulatory authorities are working to balance innovation with safety by creating flexible but strong regulatory pathways for these advanced products.

9. Growing Importance of Skilled Regulatory Professionals

As regulatory processes become more complex and digital, the demand for **trained and skilled regulatory affairs professionals** is increasing. Professionals must now understand global regulations, digital submission systems, data management, and new technologies. Continuous training and upskilling are essential to meet modern regulatory expectations.[34]

Future and Scope of Regulatory Affairs

Regulatory Affairs (RA) is becoming more important as the pharmaceutical and healthcare industries continue to grow and change. In the future, regulatory affairs will play a bigger role in ensuring that new medicines, medical devices, and healthcare technologies reach patients safely and quickly.

1. Growing Importance of Regulatory Affairs

The number of pharmaceutical products, biologics, vaccines, and medical devices is increasing every year. Because of this growth, **regulatory authorities are strengthening their rules**, and companies need skilled regulatory professionals to meet these requirements. In the future, regulatory affairs will remain essential for product approval, safety monitoring, and compliance with global laws.

2. Expansion of Digital and Electronic Regulatory Systems

In the future, most regulatory activities will be **fully digital**. Electronic submissions, online portals, and cloud-based systems will become standard. Regulatory professionals will need to understand digital tools, data management systems, and electronic submission platforms. This digital shift will improve speed, accuracy, and transparency in regulatory processes.

3. Increased Global Opportunities

Regulatory affairs offers **global career opportunities**. Pharmaceutical companies operate in many countries, and each product requires approval in different regions. Regulatory professionals who understand international regulations such as USFDA, EMA, CDSCO, and ICH guidelines will be in high demand. The scope of regulatory affairs will expand beyond national boundaries.[35]

4. Growth of Advanced and Innovative Products

The future of healthcare includes **biologics, biosimilar, gene therapy, cell therapy, personalized medicines, and digital health products**. These advanced products require new and specialized regulatory pathways. Regulatory affairs professionals will play a key role in guiding these products through complex approval processes.

5. Stronger Focus on Patient Safety and Pharmacovigilance

In the future, there will be greater emphasis on **post-marketing safety and pharmacovigilance**. Regulatory professionals will be responsible for safety reporting, risk management, and continuous monitoring of products after approval. This ensures long-term patient safety and trust in medicines.

6. Faster and Flexible Approval Pathways

Regulatory authorities are moving toward **faster and flexible approval systems** for critical medicines. Regulatory affairs professionals will help companies use fast-track, conditional, and emergency approval pathways while ensuring compliance and safety.[36]

7. Rising Demand for Skilled Regulatory Professionals

The demand for **trained regulatory affairs professionals** is increasing rapidly. Regulatory professionals must have knowledge of science, law, documentation, communication, and digital systems. This makes regulatory affairs a stable and rewarding career option with long-term growth.

8. Opportunities across Multiple Healthcare Sectors

The scope of regulatory affairs is not limited to pharmaceuticals. It extends to:

- devices
- Medical In vitro diagnostics (IVDs)
- Cosmetics
- Nutraceuticals
- Vaccines
- Biotechnology products

This wide scope offers diverse career paths in regulatory affairs.

9. Career Growth and Job Roles

In the future, regulatory professionals can grow into roles such as:

- Regulatory Affairs Executive
- Regulatory Affairs Manager
- Regulatory Strategy Specialist
- Compliance Officer
- Regulatory Consultant

These roles offer good career growth, responsibility, and global exposure.[37]

CONCLUSION

Regulatory Affairs serves as the backbone of the pharmaceutical and healthcare industries, ensuring that every phase of a product's lifecycle from discovery and preclinical development to clinical trials, regulatory submissions, and post-marketing monitoring adheres to stringent standards of quality, safety, and efficacy. Acting as the bridge between drug developers, clinical researchers, and regulatory authorities, RA professionals facilitate timely access to safe and innovative therapies while ensuring full compliance with national and international regulations. The adoption of global harmonized frameworks, including ICH guidelines, GxP principles, and standardized submission formats like CTD, eCTD, and ACTD, has streamlined regulatory processes, reduced redundancies, and improved cross-border efficiency.

Technological advancements, such as digital submission platforms, AI-driven document review, and cloud-based tracking systems like the CDSCO Sugar portal, have further enhanced operational efficiency, transparency, and patient-centric decision-making. Real-world evidence and patient-reported outcomes have become integral in evaluating a

product's performance, complementing traditional clinical trial data. Accelerated and adaptive approval pathways, strengthened post-marketing surveillance, and evolving regulations for biologics, gene therapies, and digital health products highlight the dynamic nature of RA and its critical role in public health. Looking ahead, Regulatory Affairs is expected to expand globally, offering diverse opportunities across pharmaceuticals, medical devices, in vitro diagnostics, nutraceuticals, vaccines, and biotechnology products. Skilled regulatory professionals will be essential to navigate complex, evolving regulatory landscapes, implement compliant strategies, and support the approval of advanced therapies. In essence, RA is a strategic, knowledge-driven discipline that bridges science, law, and patient care. By ensuring safe, effective, and high-quality healthcare products reach patients efficiently, Regulatory Affairs continues to safeguard public health, accelerate innovation, and drive sustainable growth in the global pharmaceutical and healthcare sectors.[38]

REFERENCES

1. Gupta P, Gupta S. Regulatory affairs in the pharmaceutical industry: an overview. J Pharm Sci Res, 2015; 7(5): 303–307.
2. Shah J, Desai D, Patel J. Role of regulatory affairs in pharmaceutical industry. *Int J Pharm Sci Rev Res*, 2014; 28(1): 1–6.
3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH guidelines. Geneva: ICH, 2023.
4. Ravikumar K, Parthasarathi RB. Drug regulatory system in India: a review. *Asian J Pharm Clin Res*, 2016; 9(2): 34–38.
5. Dhole SD, Darade RB. Indian pharmaceutical regulatory authority: review. *Int J Pharm Sci*, 2024; 2(5): 1109–1119.
6. Shah J, Gupta P, Shah S. Role of regulatory authorities in India for drug approval and clinical trials. *Int J Pharm Sci Rev Res*, 2014; 28(1): 1–6.
7. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*, 2013; 158(3): 200–207.
8. Rohilla, A., Singh, R. K., Sharma, D., Keshari, R., & Kushnoor, A., *Phases of clinical trials: A review.* International Journal of Pharmaceutical, Chemical and Biological Sciences, 2013; 3(3): 700–703.
9. Freeman, M. W., Bond, M., Murphy, B., Hui, J., et al., *Results from a Phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertension Research,* 2023; *46*: 108–118.
10. Le Tourneau, C., Lee, J. J., & Siu, L. L., *Dose escalation methods in Phase I cancer clinical trials. Journal of the National Cancer Institute,* 2009; *101*(10): 708–720.
11. Gangadhar, J., Dhana Lakshmi, G., & Durga Naresh, K., *A review on mechanisms and clinical effects of food-drug interactions. Journal of Pharma Insights and Research,* 2025; *3*(5): 244–251.
12. Sun, L., Mi, K., Hou, Y., Hui, T., Zhang, L., Tao, Y., Liu, Z., & Huang, L., *Pharmacokinetic and pharmacodynamic drug–drug interactions: Research methods and applications. Metabolites*, 2023; *13*(8): 897.
13. Sowjanya, B., & Girish, K., *A review on bioavailability and bioequivalence studies — pharmacokinetic parameters and their significance. SPER International Journal of Pharmacy and Life Sciences,* 2013; *1*(3): 1711–1721.

14. Sacks, L. V., Shamsuddin, H., Yasinskaya, Y. I., & Sherwin, C. M. T., *Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012*. *JAMA Internal Medicine*, 2014; *174*(12): 1959–1965.
15. Enablers and Barriers of Clinical Trial Participation in Adult Patients from Minority Ethnic Groups: A Systematic Review., *Trials*, 2025; *26*: 65.
16. Alhawassi, T. M., Krass, I., Pont, L. G., & Suleiman, A. A., *A global perspective of the role of pharmacovigilance in ensuring drug safety after approval. Journal of Clinical Pharmacy and Therapeutics*, 2014; *39*(6): 618–622.
17. Chowdhury, D., & Mukherjee, S., *Pharmacovigilance in India: Current status and future perspectives. Indian Journal of Pharmacology*, 2014; *46*(6): 585–590.
18. Patel, R. S., & Desai, A. S., *Current trends in pharmaceutical product development in India: Early-phase studies and exploratory formulations. Indian Journal of Pharmaceutical Education and Research*, 2018; *52*(3): 345–352.
19. Shah, V. P., & Tawakkul, M. A., *Physicochemical properties of drug substances: Implications in preformulation and API development. Journal of Pharmaceutical Sciences*, 2008; *97*(11): 4690–4703.
20. Singh, S., & Bakshi, M., Guidance on stability testing of new drug substances and products. Pharmaceutical Technology, 2000; 24(2): 48–57.
21. Patel, N. R., & Patel, J. B., *Excipient compatibility studies: Key aspect of preformulation in Indian pharmaceutical industry. International Journal of Pharmaceutical Investigation*, 2016; *6*(4): 196–203.
22. Patel, P. D., & Patel, D. R., *Exploratory development of pharmaceutical formulations in India: Preformulation and early product development strategies. Indian Journal of Pharmaceutical Education and Research*, 2019; *53*(2): 233–243.
23. Rangari, V. D., & Bhalerao, S., *Implementation of eCTD in India: Regulatory perspectives and challenges. Journal of Pharmaceutical Regulatory Affairs*, 2018; *7*(3): 101–107.
24. Saraswat, R., Raikwar, A., & Panda, S., *Streamlining regulatory documentation: Exploring the Common Technical Document (CTD) and electronic submission, with emphasis on M series according to ICH guidelines.* Asian Journal of Pharmaceutical and Clinical Research, 2024; 17(10): 1–7.
25. Ohashi, Y., & Nakamura, H., *Adoption and implementation of eCTD in Asia: Regulatory trends and practical challenges.* Drug Information Journal, 2018; 52(3): 369–378.
26. Agarwal, P., Dewangan, A., & Duggi, P., *Electronic Common Technical Document (eCTD): A review of history, benefits of implementing, challenges, modules and risks involved in eCTD publishing*. *Research & Reviews: A Journal of Drug Formulation, Development and Production*, 2016; *3*(3): 1–16.
27. Godiyal, S., *Regulatory requirements for preparation of dossier for registration of pharmaceutical products in ACTD & CTD format* [Review]. *International Journal of Drug Regulatory Affairs*, 2019; *7*(2): 51–59.
28. Panchal, V., Patel, U., Movaliya, V., Vaghela, K., Kanki, N., & Zaveri, M., *Regulatory requirement for the approval of generic drug in Vietnam as per ASEAN Common Technical Dossier (ACTD). International Journal of Drug Regulatory Affairs*, 2022; *10*(3): 66–69.
29. Singh, H., & Kumar, V., *Role of CDSCO in drug regulation and approval process in India*. *International Journal of Drug Regulatory Affairs*, 2021; *9*(2): 45–52.
30. Pawar, K. N., Gore, R. T., & Palekar, S. R., *A review on approval process and regulation of medical devices as per US FDA and CDSCO*. *International Journal of Drug Regulatory Affairs*, 2023; *11*(1): 61–70.

31. The Pharma Innovation Journal., *SUGAM pathway for pharmaceutical products in India. The Pharma Innovation Journal,* 2019; *8*(5): 244–248.
32. Topra, M. K., & Kumar, A., *Regulatory affairs in pharmaceutical industry: A review*. *International Journal of Pharmaceutical Sciences Review and Research,* 2015; *33*(1): 196–201.
33. Benjamens, S., Dhunnoo, P., & Meskó, B., *The state of artificial intelligence-based FDA-approved medical devices and algorithms*. *NPJ Digital Medicine,* 2020; *3*(118).
34. Dellepiane, N., & Woodcock, J., *Regulatory harmonization and convergence: International experiences*. *Clinical Pharmacology & Therapeutics,* 2015; *98*(3): 261–264.
35. Rägo, L., & Santoso, B., Drug regulation: History, present and future. *Drug Information Journal,* 2008; *42*(6): 629–640.
36. Marks, P. W., & Gottlieb, S., Balancing safety and innovation for cell and gene therapies. *Nature Biotechnology,* 2018; *36*(11): 989–992.
37. Patil, S. P., & Deshmukh, R. K., Career opportunities and challenges in pharmaceutical regulatory affairs. *International Journal of Pharmaceutical Sciences Review and Research,* 2019; *59*(2): 151–156.
38. Dellepiane, N., & Woodcock, J., Regulatory harmonization and convergence: Global perspectives. *Clinical Pharmacology & Therapeutics,* 2015; *98*(3): 261–26.